Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 79

Results For "clinical"

2937 News Found

Zydus Lifesciences reports Q1 FY26 net profit at Rs. 1,466.8 Cr
News | August 13, 2025

Zydus Lifesciences reports Q1 FY26 net profit at Rs. 1,466.8 Cr

The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY


Pfizer launches 20-valent Pneumococcal Conjugate Vaccine for adults in India
News | August 12, 2025

Pfizer launches 20-valent Pneumococcal Conjugate Vaccine for adults in India

Pfizer's vaccine helps protect against clinically relevant 20 serotypes responsible for a majority of invasive and non-invasive pneumococcal disease


Sartorius and Nanotein Technologies partner to advance cell therapy manufacturing
Biotech | August 12, 2025

Sartorius and Nanotein Technologies partner to advance cell therapy manufacturing

Under an exclusive distribution agreement, Sartorius Stedim Biotech will offer Nanotein’s lead products globally


Asian Institute of Nephrology & Urology expands hospital in Banjara Hills, Hyderabad
News | August 12, 2025

Asian Institute of Nephrology & Urology expands hospital in Banjara Hills, Hyderabad

AINU is set to accelerate its expansion footprint, enhance operational capabilities


Cohance to invest $10 million to expand cGMP bioconjugation capabilities in US
News | August 12, 2025

Cohance to invest $10 million to expand cGMP bioconjugation capabilities in US

NJ Bio is currently executing a major new program for an existing innovator customer with multiple ADC candidates in their pipeline


Primelaze introduces Q-Switched Nd:YAG laser technology in India for skin treatments
News | August 08, 2025

Primelaze introduces Q-Switched Nd:YAG laser technology in India for skin treatments

The Q-Switched Nd:YAG system is suitable for all skin types and offers versatility in treating dermal and epidermal pigmentation


AbbVie announces positive Phase 3 results for Upadacitinib in Alopecia Areata
Clinical Trials | August 06, 2025

AbbVie announces positive Phase 3 results for Upadacitinib in Alopecia Areata

The average baseline SALT score was 83.8, indicating about 16% scalp hair coverage


Vertex faces regulatory delays for Journavx and reports VX-993 Phase 2 trial failure
News | August 06, 2025

Vertex faces regulatory delays for Journavx and reports VX-993 Phase 2 trial failure

Treatment with the selective NaV1.8 pain signal inhibitor VX-993 after bunionectomy surgery did not meet the primary endpoint